drugset
drugset / Trial / NCT06079112

9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer

NCT06079112 ↗

Phase 1/2 Recruiting 100 enrolled Mabwell (Shanghai) Bioscience Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a phase Ib/II, open-label, multicenter clinical study to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of 9MW2821 combined with Toripalimab injection in subjects with local advanced or metastatic urothelial cancer.

Timeline

Start
2023-09-27
Primary completion
2026-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject 9MW2821 Monoclonal antibody 1 mg/kg Intravenous
Subject 9MW2821 Monoclonal antibody 1.25 mg/kg Intravenous
Subject 9MW2821 Monoclonal antibody 1.5 mg/kg Intravenous
Subject Toripalimab Monoclonal antibody 240 mg Intravenous

Indications

urothelial carcinoma